In a significant development for the medical marijuana industry, the U.S. Department of the Treasury and the Internal Revenue Service (IRS) announced their intention to issue guidance concerning the federal tax implications of the recent DOJ Final Order. This order aligns with President Trump’s Executive Order aimed at enhancing research related to medical marijuana and cannabidiol, which was enacted in December 2025.

The Executive Order directs the Attorney General to facilitate reclassification of medical marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). This change could potentially ease restrictions on research and financial operations within the industry, which has historically faced various legal challenges.

The anticipated IRS guidance will be crucial for stakeholders as it outlines how the new classification affects tax obligations. As discussions around regulatory frameworks intensify, this move signifies the government’s acknowledgment of the evolving landscape surrounding medical marijuana and its potential economic implications.

Market Impact Snapshot

• Bitcoin: Neutral
• Gold: Neutral
• Silver: Neutral
• Overall Market: Neutral

The market labels above reflect a short-term informational bias derived from the official announcement summarized in this article. They do not constitute investment advice, financial advice, trading advice, or a recommendation to buy, sell, or hold any asset.

Official Source: US Treasury